» Articles » PMID: 11431338

Conversion from a Paracrine to an Autocrine Mechanism of Androgen-stimulated Growth During Malignant Transformation of Prostatic Epithelial Cells

Overview
Journal Cancer Res
Specialty Oncology
Date 2001 Jun 30
PMID 11431338
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Normal adult prostate epithelium of both human and rat origin was transplanted with Matrigel into intact or androgen-ablated (i.e., castrated) nude mice. Within these transplants, an influx of mouse mesenchymal cells was one of the earliest events to occur resulting in the development of a collar of smooth muscle cells and fibroblasts surrounding the transplanted epithelium. A subset of these surrounding stromal cells express androgen receptor (AR). The surrounded transplanted epithelium initially expresses high molecular weight cytokeratins characteristic of prostatic basal cells and AR. In both intact and androgen-ablated hosts, this epithelium subsequently develops a patent lumen producing a rudimentary glandular acini. Only in the nonablated hosts, however, do these rudimentary acini undergo a further proliferative growth phase, as determined by Ki67 immunocytochemical stainings and the development of a low molecular weight cytokeratin positive layer of luminal (i.e., secretory) epithelial cells. Because AR is expressed in both the donor epithelium and host (i.e., mouse) stromal cells, this androgen-stimulated growth response could involve either autocrine pathways initiated within donor normal adult epithelial cells themselves or paracrine pathways initiated within the AR-expressing subset of mouse stromal cells. To resolve this issue, mice carrying the testicular feminized mutation in the X-linked AR gene were cross-bred to AR-wt nude mice to produce AR-null nude male mice. None of the cells in these AR-null nude male mice express functional AR protein. Therefore, these animals can be used to prevent any possibility of host stromal cell paracrine involvement in initiating an androgen-stimulated growth response when normal adult or malignant prostatic epithelial cells are transplanted into these null hosts. In these AR-null nude male mice, the androgen-stimulated growth of normal adult prostatic epithelial cells did not occur (i.e., androgen-induced growth response of normal prostatic epithelial cells requires stromal cell paracrine involvement). In contrast, using four different prostatic cancer models (i.e., human PC-82, human LNCaP, human LAPC-4, and rat R3327G), the androgen-stimulated growth of prostatic cancer cells occurred identically in both AR-null and AR-wt nude male mice (i.e., a direct autocrine mechanism is responsible for androgen-stimulated growth of malignant prostatic epithelial cells). In summary, a fundamental change in the mechanism for androgen-stimulated growth occurs during the transformation from normal to malignant prostatic epithelial cells.

Citing Articles

Prostatic lineage differentiation from human embryonic stem cells through inducible expression of NKX3-1.

Wang S, Yu Y, Li Y, Zhang T, Jiang W, Wang X Stem Cell Res Ther. 2024; 15(1):274.

PMID: 39218930 PMC: 11367998. DOI: 10.1186/s13287-024-03886-y.


Single-cell RNA sequencing of human prostate basal epithelial cells reveals zone-specific cellular populations and gene expression signatures.

Vellky J, Wu Y, Moline D, Drnevich J, Maienschein-Cline M, Valyi-Nagy K J Pathol. 2023; 262(2):212-225.

PMID: 37984408 PMC: 10842206. DOI: 10.1002/path.6227.


Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer.

Leach D, Fernandes R, Bevan C Endocr Oncol. 2023; 2(1):R112-R131.

PMID: 37435460 PMC: 10259329. DOI: 10.1530/EO-22-0065.


Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen.

Kukkonen K, Autio-Kimura B, Rauhala H, Kesseli J, Nykter M, Latonen L Endocr Relat Cancer. 2022; 29(12):717-733.

PMID: 36219867 PMC: 9644224. DOI: 10.1530/ERC-22-0108.


Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.

Aggarwal R, Starodub A, Koh B, Xing G, Armstrong A, Carducci M Clin Cancer Res. 2022; 28(18):3979-3989.

PMID: 35816286 PMC: 9475238. DOI: 10.1158/1078-0432.CCR-22-0175.